Single-port robotic partial nephrectomy: impact on perioperative outcomes and hospital stay.

IF 2.6 4区 医学 Q2 UROLOGY & NEPHROLOGY
Umberto Carbonara, Daniele Amparore, Leonardo D Borregales, Anna Caliò, Chiara Ciccarese, Pietro Diana, Selcuk Erdem, Laura Marandino, Michele Marchioni, Constantijn H J Muselaers, Carlotta Palumbo, Nicola Pavan, Angela Pecoraro, Eduard Roussel, Hannah Warren, Zhen-Jie Wu, Riccardo Campi, Riccardo Bertolo
{"title":"Single-port robotic partial nephrectomy: impact on perioperative outcomes and hospital stay.","authors":"Umberto Carbonara,&nbsp;Daniele Amparore,&nbsp;Leonardo D Borregales,&nbsp;Anna Caliò,&nbsp;Chiara Ciccarese,&nbsp;Pietro Diana,&nbsp;Selcuk Erdem,&nbsp;Laura Marandino,&nbsp;Michele Marchioni,&nbsp;Constantijn H J Muselaers,&nbsp;Carlotta Palumbo,&nbsp;Nicola Pavan,&nbsp;Angela Pecoraro,&nbsp;Eduard Roussel,&nbsp;Hannah Warren,&nbsp;Zhen-Jie Wu,&nbsp;Riccardo Campi,&nbsp;Riccardo Bertolo","doi":"10.1177/17562872231172834","DOIUrl":null,"url":null,"abstract":"<p><p>Single-port (SP) robotic surgery is a novel technology and is at the beginning of its adoption curve in urology. The goal of this narrative review is to provide an overview of SP-robotic partial nephrectomy (PN) 4 years after the introduction of the da Vinci SP dedicated platform, focusing on perioperative outcomes, length of stay, and surgical technique. A nonsystematic review of the literature was conducted. The research included the most updated articles that referred to SP robotic PN. Since its commercial release in 2018, several institutions have reproduced robotic PN by using the SP platform, both <i>via</i> a transperitoneal and a retroperitoneal approach. The published SP-robotic PN series are generally based on preliminary experiences by surgeons who had previous experience with conventional multi-arms robotic platforms. The reported outcomes are encouraging. Overall, three studies reported that SP-robotic PN cases had nonsignificantly different operative time, estimated blood loss, overall complications rate, and length of stay compared to the conventional 'multi-arms' robotic PN. However, in all these series, renal masses treated by SP had overall lower complexity. Moreover, two studies underlined decreased postoperative pain as a major pro of adopting the SP system. This should reduce/avoid the need for opioids after surgery. No study compared SP-robotic <i>versus</i> multi-arms robotic PN in cost-effectiveness. Published experience with SP-robotic PN has reported the feasibility and safety of the approach. Preliminary results are encouraging and at least noninferior with respect to those from the multi-arms series. Prospective comparative studies with long-term oncologic and functional results are awaited to draw more definitive conclusions and better establish the more appropriate indications of SP robotics in the field of PN.</p>","PeriodicalId":23010,"journal":{"name":"Therapeutic Advances in Urology","volume":"15 ","pages":"17562872231172834"},"PeriodicalIF":2.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f0/f7/10.1177_17562872231172834.PMC10265377.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562872231172834","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Single-port (SP) robotic surgery is a novel technology and is at the beginning of its adoption curve in urology. The goal of this narrative review is to provide an overview of SP-robotic partial nephrectomy (PN) 4 years after the introduction of the da Vinci SP dedicated platform, focusing on perioperative outcomes, length of stay, and surgical technique. A nonsystematic review of the literature was conducted. The research included the most updated articles that referred to SP robotic PN. Since its commercial release in 2018, several institutions have reproduced robotic PN by using the SP platform, both via a transperitoneal and a retroperitoneal approach. The published SP-robotic PN series are generally based on preliminary experiences by surgeons who had previous experience with conventional multi-arms robotic platforms. The reported outcomes are encouraging. Overall, three studies reported that SP-robotic PN cases had nonsignificantly different operative time, estimated blood loss, overall complications rate, and length of stay compared to the conventional 'multi-arms' robotic PN. However, in all these series, renal masses treated by SP had overall lower complexity. Moreover, two studies underlined decreased postoperative pain as a major pro of adopting the SP system. This should reduce/avoid the need for opioids after surgery. No study compared SP-robotic versus multi-arms robotic PN in cost-effectiveness. Published experience with SP-robotic PN has reported the feasibility and safety of the approach. Preliminary results are encouraging and at least noninferior with respect to those from the multi-arms series. Prospective comparative studies with long-term oncologic and functional results are awaited to draw more definitive conclusions and better establish the more appropriate indications of SP robotics in the field of PN.

Abstract Image

Abstract Image

Abstract Image

单孔机器人部分肾切除术:对围手术期预后和住院时间的影响。
单端口(SP)机器人手术是一项新技术,在泌尿外科应用曲线的开始。这篇叙述性综述的目的是在引入达芬奇SP专用平台4年后,对SP机器人部分肾切除术(PN)进行概述,重点关注围手术期结果、住院时间和手术技术。对文献进行了非系统回顾。该研究包括了涉及SP机器人PN的最新文章。自2018年商业发布以来,已有多家机构使用SP平台通过经腹膜和后腹膜途径复制机器人PN。已发表的sp -机器人PN系列通常基于先前具有传统多臂机器人平台经验的外科医生的初步经验。报告的结果令人鼓舞。总体而言,有三项研究报告称,与传统的“多臂”机器人PN相比,sp机器人PN病例的手术时间、估计出血量、总并发症发生率和住院时间没有显著差异。然而,在所有这些系列中,SP治疗肾肿块的总体复杂性较低。此外,两项研究强调减少术后疼痛是采用SP系统的主要优点。这将减少/避免手术后对阿片类药物的需求。没有研究比较sp机器人和多臂机器人PN的成本效益。已发表的sp -机器人PN的经验报告了该方法的可行性和安全性。初步结果是令人鼓舞的,至少不逊色于那些来自多臂系列。等待长期肿瘤学和功能结果的前瞻性比较研究,以得出更明确的结论,并更好地建立SP机器人在PN领域更合适的适应症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.70
自引率
0.00%
发文量
39
审稿时长
10 weeks
期刊介绍: Therapeutic Advances in Urology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of urology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in urology, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest across all areas of urology, including treatment of urological disorders, with a focus on emerging pharmacological therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信